Global Vision
The Barcelona Health Hub is a nonprofit that seeks to advance digital health innovation by bringing together start-ups, investors, health care institutions and corporations.
New funding mechanisms are required to give more momentum to prevention in the community and thereby relieve pressure on overburdened health care providers like the UK National Health Service. So says Simon Radford, a director at global thinktank the Milken Institute, which sees a solution in more funding for community-level prevention.
China's medical equipment industry is growing rapidly, driven by limited domestic presence in high-cost segments and increasing adoption of local products in areas like monitoring equipment, defibrillators, and ventilators. International giants dominate the high-end market, but domestic companies such as Neusoft Medical Systems and Mindray Medical are making significant strides.
Close collaboration between industry, academia and government in employing artificial intelligence could solve the looming threat of antimicrobial resistance, a new report co-authored by Google says.
While Japan looks set to further improve policies to support ventures and ease market entry this year, these will contrast with ongoing reimbursement price controls.
As 2025 begins, the pharma industry is abuzz with discussions on pipeline strategies and China's growing role. With 30% of large pharma licensing deals now involving Chinese biotech, we take a whistlestop tour of the companies and regions driving this innovation.
As efforts to improve diversity in clinical trials gain momentum globally, regulators in the UK, the EU, Canada, Australia and Japan were asked about their efforts to support representative enrolment.
In 2023, China emerged as the second largest exporter in the global biopharmaceutical pipeline. While innovation, international expansion, and commercialization remain pivotal, the industry's growth has increasingly relied on industrial efforts due to less active capital markets.
France’s medtech sector is strong, growing and innovative. In Vivo spoke to several French medtech leaders about the unique features and pitfalls their industry may face.
Asia-Pacific continues to solidify its position as a key location for clinical trials, with China in particular dominating such activity in the region, and increasingly globally, a Citeline White Paper shows.
The pharma industry arguably suffered none of the downside risks that were possible during the first Trump administration, and their relationship with Biden could not have gone much worse. And while they may hope a Trump return could help their fortunes, having RFK Jr. supervising the FDA is likely not the prescription they want.
India is seeing a flurry of activity with big pharma either establishing or expanding their global capability centers in the country. Can these hubs reshape the contours of industry’s operating model across a range of functions and perhaps spawn a pipeline of new leaders along the way?
As China faces the potential loss of a big customer base, the US off-patent industry starts to look for new relationships elsewhere. While building domestic manufacturing capabilities would be the ultimate American dream, the government has yet to offer the carrot, not just the stick.
While Japanese firms still dominate the money spinners in Asia, companies from China and, lesser so, India are starting to stand out from the crowd.
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
A public interest group has accused the pharma major of using excessive pricing to bolster sales of blockbuster Humira, consequently damaging the health of Dutch patients.
APrevent, a laryngeal implant developer from Taiwan, was named the overall winner of the annual MedTech Innovator APAC accelerator award for 2024. Awards managing director Fredrik Nyberg talked to In Vivo about the rising importance of the APAC region’s hub of companies providing innovative medtech.
The potential of the UK’s life sciences sector continues to be critically misunderstood and should be the cornerstone of both society and the economy, according to Teva’s CEO Richard Francis.
New rules on health technology assessments in Spain make room for real-world evidence and early dialog.
Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.